

Food and Drug Administration Rockville MD 20857

A1 16

MAR | 2 | 1997

Re: VISX Excimer Laser System Docket No. 97E-0064

Stephen G. Kunin Deputy Assistant Commissioner for Patent Policy and Projects Office of the Assistant Commissioner for Patents U.S. Patent and Trademark Office Crystal Park Building 2, Suite 919 Washington, D.C. 20231

Dear Mr. Kunin:

This is in regard to the application for patent term extension for U.S. Patent No. 4,718,418 filed by VISX, Incorporated under 35 U.S.C. § 156. The medical device claimed by the patent is VISX Excimer Laser System, which was assigned Premarket Approval Application (PMA) No. 910062.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1), and interpreted by the courts in Glaxo Operations UK Ltd. v. Quigg, 706 F. Supp 1224 (E.D. Va. 1989), aff'd, 894 F. 2d 392 (Fed. Cir. 1990).

The PMA was approved on September 29, 1995, which makes the submission of the patent term extension application on November 28, 1995, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the Federal Register, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely.

Ronald L. Wilson, Director Health Assessment Policy Staff

Office of Health Affairs

cc:

Tom M. Moran Cooley, Godword, Castro, Huddleson & Tatum Five Palo Alto Square 3000 El Camino Real Palo Alto, CA 94306-2155